Endoglin for tumor imaging and targeted cancer therapy

Abstract

Introduction: Although cancer treatment has evolved substantially in the past decades, cancer-related mortality rates are still increasing. Therapies targeting tumor angiogenesis, crucial for the growth of solid tumors, mainly target vascular endothelial growth factor (VEGF) and have been clinically applied during the last decade. However, these therapies have not met high expectations, which were based on therapeutic efficacy in animal models. This can partly be explained by the upregulation of alternative angiogenic pathways. Therefore, additional therapies targeting other pro-angiogenic pathways are needed.

Areas covered: The transforming growth factor (TGF)-β signaling pathway plays an important role in (tumor) angiogenesis. Therefore, components of this pathway are interesting candidates for anti-angiogenic therapy. Endoglin, a co-receptor for various TGF-β family members, is specifically overexpressed in tumor vessels and endoglin expression is associated with metastasis and patient survival. Therefore, endoglin might be a good candidate for anti-angiogenic therapy. In this review, we discuss the potential of using endoglin to target the tumor vasculature for imaging and therapeutic purposes.

Expert opinion: Considering the promising results from various in vitro studies, in vivo animal models and the first clinical trial targeting endoglin, we are convinced that endoglin is a valuable tool for the diagnosis, visualization and ultimately treatment of solid cancers.

Keywords::

• angiogenesis
• CD105
• microvessel density
• TGF-β
• TRC105

Acknowledgements

We would like to thank the members of our lab for valuable discussions. Furthermore, we are grateful to CFM Sier (LUMC, Department of Surgery), C Theuer (Tracon Pharmaceuticals, San Diego, USA) and M-J Goumans (LUMC, Department of Molecular Cell Biology) for critically reviewing the manuscript.

Notes

This box summarizes key points contained in the article.